Haemonetics (HAE) Depreciation & Amortization (CF) (2009 - 2026)

Haemonetics has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $27.1 million in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 5.73% year-over-year to $27.1 million in Q2 2026; TTM through Jun 2026 was $110.1 million, a 4.46% decrease from a year earlier, with the FY2026 full-year figure at $111.7 million, down 3.35% from the prior year.
• Depreciation & Amortization (CF) was $27.1 million for Q2 2026 at Haemonetics, down from $27.3 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $29.2 million in Q3 2024, with the low at $22.4 million in Q3 2022.
• Average Depreciation & Amortization (CF) over 5 years is $26.0 million, with a median of $27.1 million recorded in 2026.
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) decreased 10.33% in 2022, then climbed 26.96% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $23.6 million in 2022, then retreated by 0.17% to $23.5 million in 2023, then advanced by 23.35% to $29.0 million in 2024, then retreated by 5.65% to $27.4 million in 2025, then retreated by 1.0% to $27.1 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $27.1 million (Q2 2026), $27.3 million (Q1 2026), and $27.4 million (Q4 2025), per Business Quant data.